Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (SPRO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
spro · stock forecast · 13 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.74
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.80 | ↑ 2.23% |
1-day model range: $2.78–$2.82. Peak: $2.82 (+2.23%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $3 | +20.2% |
| 2028 | $4 | +32.3% |
| 2029 | $4 | +39.0% |
| 2030 | $4 | +42.5% |
| 2031 | — | +44.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SPRO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-01-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-20 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2024-12-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-18 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2024-11-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-06 | TD Cowen | Upgrade ↑ | Hold→Buy |
| 2024-05-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Spero Therapeutics, Inc. (SPRO) stock. Of the recent 43 rating actions, 2 were upgrades and 8 were downgrades. 13 analysts currently cover SPRO.
Analyst Recommendation Trends
SPRO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$26M
↑ 696.9% YoY
Revenue Next Year
$1M
↓ 96.9% YoY
EPS This Year
$-0.10
EPS Next Year
$0.67
↓ 770.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast SPRO EPS of $-0.10 for the current fiscal year, based on estimates from 1 analysts. The SPRO revenue forecast is $26M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SPRO stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SPRO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The SPRO short-term stock prediction for tomorrow is $2.80 (+2.23%). The SPRO stock price prediction for 2027 estimates an average of $3. The SPRO stock prediction for 2030 projects a range of $4–$4.
Spero Therapeutics, Inc. trades on NASDAQ under the ticker SPRO. The SPRO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 46% of covering analysts.
Frequently asked questions
SPRO forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month SPRO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.74.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.